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EditorialOsteoarthritis or osteoarthrosis: the definition of inflammation becomes
a semantic issue in the genomic era of molecular medicine
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§Kaplan Cancer Center, New York, New York, U.S.A.Osteoarthritis (OA) or osteoarthrosis? Reports in the last
decade have suggested that human OA-affected chondro-
cytes and activated macrophages share the release of
similar inflammatory mediators. In spite of the superinduc-
tion of inflammatory mediators by OA-affected chondro-
cytes, the unique architecture of cartilage (avascular,
aneural and alymphatic) when inflamed at the molecular
level, does not qualify for the typical definition of inflamma-
tion (redness and swelling with heat and pain—rubor et
tumor cum calore et dolor) due to the semantics and the
history of the word ‘inflammation’. The genomic revolution
provides access to tools for examining a single event in the
context of the whole genome. Use of this facility can lead to
new ways of understanding complex pathophysiological
conditions such as inflammation. From research laborato-
ries to clinical settings, inflammation is now perceived
differently although the molecular events remain the same.
The present editorial highlights semantic issues using one
example of an ‘inflammatory disease’: OA.History of inflammation
Redness and swelling with heat and pain—rubor et
tumor cum calore et dolor—were first documented as the
cardinal signs of inflammation by Cornelius Celsius in the
first century CE (30 BC to 38 AD). He defined inflammation
as an entity using a singular rather than a plural noun,
implying that it might be a single process or type of
process1. However, the history of inflammation is long and
colorful, intimately linked to that of wounds, wars and
infections. In his marvelous book, The Healing Hand: Man
and Wound in Ancient World, Majno has assembled
ancient descriptions of inflammation written long before
Celsius put his stamp on the field2. Following the rather
slow development of the biological and clinical sciences in
the ensuing centuries, the invention of the microscope and
the discovery that there was no such thing as spontaneous1generation of life forms led to a sudden burgeoning of
studies on the mechanisms of inflammation in the nine-
teenth and early twentieth centuries. These include exami-
nation of the vascular and cellular events in thin transparent
membranes in vivo by Cohnheim, investigation of phago-
cytosis by Metchnikoff, of the role of antibodies by Ehrlich,
of complement by Bordet and the development of the
concept of endogenous mediators by Lewis2. In the latter
part of the twentieth century, the development of new
technologies including electron and fluorescence
microscopy, histopathology, biochemistry, molecular biol-
ogy and genetic engineering has facilitated the remodeling
of the concept of ‘inflammation’ in molecular medicine. The
last decade has introduced several new technologies,
including Real Time PCR, Gene Chip technology and
Proteomics. These not only allow us to look at minor
changes in pathophysiological conditions, but at global
effects on gene and protein expression as they relate to
expression of a single gene or protein.
The purpose of this editorial is to discuss one particular
human pathophysiological condition (OA), which has cer-
tain features of inflammation but which breaks the rules for
the definition of inflammation as described below.Osteoarthritis or osteoarthrosis: which is more
appropriate?
Pathologists and radiologists at the turn of the century
differentiated two principal forms of chronic arthritis: (1)
atrophic arthritis with synovial inflammation and erosion or
atrophy of cartilage and bone (e.g. rheumatoid arthritis) and
(2) hypertropic arthritis, characterized by focal loss of
cartilage, little evidence of the typical form of inflammation,
and by growth (hypertrophy) of adjacent bone and soft
tissue3. The latter group became synonymous with OA. In
the 1960s and 1970s major research interest increasingly
focused on inflammatory arthropathies, with OA often being
used in clinical and laboratory studies as a ‘non-
inflammatory’ control, or even as a surrogate for normal
joint tissue. Such usage encouraged the term osteoarthro-
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considered an inherently non-inflammatory disorder of
movable joints characterized by deterioration of articular
cartilage and the formation of new bone at the joint sur-
faces and margins5. The synovial fluid in OA, in contrast to
that in RA, typically contains few neutrophils (<3000/mm3)
and, except in advanced disease, the synovium itself does
not exhibit significant cellular proliferation or infiltration by
inflammatory leukocytes. OA also differs from RA in that it is
not a systemic disease, but one in which an ‘inflammatory
component’ seems to be restricted in the cartilage and
bone. The molecular pathogenesis of OA has been increas-
ingly elucidated by studying events within the articular
cartilage that maintain cartilage homeostasis. For example,
alteration in the dynamic equilibrium between synthesis
and degradation of the matrix by chondrocytes has been
implicated as a first step in the degeneration of articular
cartilage resulting in OA6,7.OA-AFFECTED CHONDROCYTE: ‘A LARGE ACTIVATED
MACROPHAGE’
The normal size of an activated macrophage is approxi-
mately 3.8 m, whereas that of an OA-affected chondro-
cyte is approximately 25 m. Figure 1 summarizes some of
the common inflammatory mediators released by activated
macrophages and chondrocytes. This OA-chondrocyte
may behave to some extent like a ‘large macrophage’ with
respect to production of some of the inflammatory
mediators.Fig. 1. Common inflammatory mediators released by activated macrophages and OA-affected cartilage. The data is compiled from
References 17–24.REGULATION OF INFLAMMATORY MEDIATORS IN NORMAL AND
OA-AFFECTED CARTILAGE
When compared with normal cartilage, OA-affected car-
tilage shows superinduction of inflammatory mediators in in
vitro and ex vivo conditions. A summary of inflammatory
mediators increased in OA-affected as compared with
normal cartilage is presented in Fig. 2. Real Time PCR has
been used to demonstrate upregulation of various proin-
flammatory genes in human OA-affected as compared with
normal cartilage (Fig. 2A). As can be seen in the figure, the
scale for expression of various mRNAs in normal human
cartilage is very broad and can vary from 2 to 50,000
transcripts for a particular gene. Up-regulation of the IL-1
gene, normally transcribed in low abundance, and the IL-6
and IL-8 genes, normally transcribed in high abundance, is
clearly demonstrated. There is significant up-regulation of
TNF convertase (TACE), which regulates the release of
soluble TNF but little change in aggreganase mRNA
(ADMP-2). There is a reduction in the amount of mRNAOA cartilage: a unique inflammatory tissue
Articular cartilage is avascular, alymphatic and aneural in
nature and OA does not seem to comply with the definitions
of inflammation typified by the four cardinal signs of Celsius
described above. Because of its unique architecture, the
cartilage in OA does not show the redness, swelling and
heat that result from increases in vascular permeability and
leakage during inflammation at other sites. Because there
is no extravasation of body fluids and inflammatory cells,
granulation tissue is not formed in OA. Because there are
no nerves in cartilage, there is no painful sensation in OA
cartilage during early stages of the disease.
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OA-affected cartilage. (A) Real time PCR of mRNA transcripts in
normal and OA-affected cartilage. Equal amounts of DNAase
treated total RNA were used to prepare cDNAs, which were PCR
amplified in triplicate using specific primers by the TaqMan
Method25. Fluorescence was measured during cycling reactions
and the increase in fluorescence after subtraction of baseline
fluorescence was plotted. The numbers of mRNA transcripts were
estimated [pre-developed assay reagents (PDARs), fluorescent
labeled], after normalization to GAPDH. Quantification of the
transcripts was performed assuming there is a single copy of a
gene using genomic DNA. Statistical analysis of the data was
performed on grouped individual data where N=10 (Fig. 2(A), (B)).
The P values were <0.01. (B) Spontaneous production of inflam-
matory mediators by normal and OA-affected cartilage in vitro17.
Human normal and OA cartilage was incubated in ex vivo con-
ditions in triplicate as previously reported18. IL-1 and TNF were
estimated by ELISA and represented as pg/ml/100 mg of cartilage.
IL-6, IL-8, MCP-1 and IL-18 were represented as ng/ml/g of
cartilage. PGE2 was represented as ng/ml and NO as M/g of
cartilage. N=3, P≤0.01. (C) Gene chip analysis of selected proin-
flammatory mediators and stress genes in normal and OA-affected
cartilage. The human Affymetrix U95 gene chip was probed with a
pool (N=10) of normal and OA-affected cartilage RNAs. The data
is presented as fold increase, normalizing the values to those of
GAPDH. The levels of OA transcripts that showed a minimum of
1.75-fold increase above normal are summarized.encoding the matrix component glucosamine glycans
(GAG) confirming a previous report that this is down-
regulated in OA8. Enzyme linked immunosorbent assay
(ELISA) or radio immunoassay (RIA) have been used to
measure the amount of mediators released (Fig. 2B).
These vary from pg/g of cartilage for IL-1 to ng/g for IL-8and IL-6. Significantly increased levels of IL-18, PGE2, NO,
monocyte chemoattractant protein-1 (MCP-1), IL-8, IL-1
and TNF are also observed. Increased levels of NO,
PGE2, IL-6, IL-1 and TNF have been reported by others to
have detrimental effects on cartilage homeostasis including
collagen metabolism and to impact on cartilage repair in
vitro and in vivo9. As assayed by gene chip technology (Fig.
2C), various other genes are found to be over-expressed.
These include matrix metalloproteases (MMP)-1, 3, 7, 9, 10
and 13, and stress induced genes such as TNF stimulated
gene-6 (TSG-6) and heat shock protein 70 (HSP70), heme
oxygenase, manganese superoxide dismutase (MnSOD)
and myeloperoxidase. Many of these are known to alter
cartilage homeostasis by up-regulating a network of pleio-
tropic inflammatory mediators, such as IL-1 and TNF
together with their interleukin 1 converting enzymes (ICE)
and TACE, as well as cytokine receptors including IL-1RI,
TNF-p55 and TNF-p7510. Other investigators have also
reported up-regulation of membrane type (MT)-MMP, plas-
minogen activators/plasmin system and cathepsin B11. One
of our most intriguing findings utilizing the gene chip array
was the two-fold increase in induction of the signaling
transcription factor, NFB, in OA as compared with normal
cartilage. Activated NFB routes various inflammatory
pathways induced by IL-1, TNF, biochemical and
mechanical/oxidative stress pathways12. Inhibition of NFB
in vitro in OA cartilage in ex vivo conditions inhibits much of
the action of the inflammatory mediators13.
At least two connections have been made between
elevation of biochemical markers of inflammation and pro-
gression of structural changes in OA joints. It has been
suggested that elevation in cartilage oligomeric protein
(COMP) may reflect synovitis14 while elevation in
C-reactive protein (CRP) may be associated with long
term radiographic progression15. Conversely, intraarticular
injection of corticosteriods in OA joints with consequent
reduction in output of the inflammatory components are
clearly associated with short-term improvement. The
improvements include reduction of symptoms, minimization
of functional disabilities and limitation of progression of
structural changes16.
Claude Bernard first suggested that the purpose of all
physiological processes is to keep the internal environment
the way cells like it. This responsibility of maintaining
cartilage homeostasis is entrusted to chondrocytes. It
seems the ‘activated chondrocytes’ observed in OA may
not only be a target, but also an instigator in the disease
process, due to autocrine production of inflammatory
mediators.
In conclusion, we have entered a new era in the concep-
tualization of the pathogenesis of OA. The debate, ‘Osteo-
arthritis vs osteoarthrosis’, must be reframed. If we require
of inflammatory processes all of the classical signs of
inflammation (e.g., rubor, color, dolor, etc.), then the narrow
concept of OA as a biomechanically driven process inter-
rupted by brief and episodic inflammation will prevail.
However, in the modern genomic era, ‘inflammation’ can
alternatively be seen as a process characterized by the
release and activation of toxic cellular mediators which
promote tissue injury, resulting in some, but not all, of the
classical signs of inflammation, including ‘functia laesa’,
loss of function. OA cartilage is a rich source of such
inflammatory mediators, a site of activated cytokine pro-
duction and of prodigious amounts of both NO and PGE2.
OA cartilage can be viewed as an inflamed tissue, brim-
ming with phylogistic products that could serve as targets
for future pharmacological intervention. Which conceptual
4 M. G. Attur et al.: Editorialframework shall we choose, Osteoarthritis or osteo-
arthrosis? The implications are clear: exciting interventional
‘antiinflammatory’ strategies for the former, pharmaco-
logical nihilism for the latter.Acknowledgments
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